Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8 + T cells combined with a DC vaccine

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 130-134

  Lutz Nicoladoni, Christina ^a   Wallner, Stephanie ^a   Stoitzner, Patrizia ^a   Pircher, Magdalena ^a   Gruber, Thomas ^a   Wolf, Anna Maria ^a   Gastl, Günther ^a   Penninger, Josef M ^b   Baier, Gottfried ^a   Wolf, Dominik ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Adoptive T cell transfer; Cbl b; dendritic cell; hyperactive T cells

Indexed keywords

ANTINEOPLASTIC AGENT; CBL PROTEIN; CD28 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; CELL PROTECTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MONOTHERAPY; MOUSE; NEOPLASM; NONHUMAN; TUMOR GROWTH; VACCINATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-CBL; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MUS;

EID: 84855457378     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.11     Document Type: Article

References (19)

1. Powell DJJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptivetransfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. JImmunol 2006; 177: 6527-6539. (Pubitemid 44628872)
2. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129. (Pubitemid 44547756)
3. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
4. Wohlfert EA, Callahan MK, Clark RB. Resistanceto CD4+CD25+ regulatory Tcells and TGF-beta in Cbl-b\-/\- mice. J Immunol 2004; 173: 1059-1065.
5. Adams CO, Housley WJ, Bhowmick S,Cone RE, Rajan TV, Forouhar Fet al.Cbl-b(\-/\-) T cells demonstrate in vivo resistance to regulatory T cells but a context-dependent resistance to TGF-beta. J Immunol 2010; 185: 2051-2058.
6. Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, Wada T et al. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med 2007; 204: 879-891. (Pubitemid 46631616)
7. Chiang JY, Jang IK, Hodes R, Gu H. Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest 2007; 117: 1029-1036. (Pubitemid 46556759)
8. Yang T, Martin ML, Nielsen JS, Milne K, Wall EM, Lin W et al. Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively trans-ferred CD8+ T cells lacking the Cbl-b gene. Cancer Immunol Immunother 2009; 58: 1865-1875.
9. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117.
10. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H et al. Regulatory Tcells reversibly suppress cytotoxic Tcell function independent of effector differentiation. Immunity 2006; 25: 129-141. (Pubitemid 44066829)
11. Moutsopoulos NM, Wen J, Wahl SM. TGF-beta and tumors\-an ill-fated alliance. Curr Opin Immunol 2008; 20: 234-240.
12. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70: 99-108.
13. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG et al. Immunity to murine prostatictumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 2009; 69: 6256-6264.
14. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW et al. Enhanced antitumor activity induced byadoptive T-cell transfer and adjunctive useof the histone deacetylase inhibitor LAQ824. Cancer Res 2009; 69: 8693-8699.
15. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV et al. Cyclophos-phamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009; 69: 4309-4318.
16. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008; 28: 109-126. (Pubitemid 351507425)
17. Stromnes IM, Blattman JN, Tan X, Jeevanjee S, Gu H, Greenberg PD. Abrogating Cbl-b in effector CD8(+) Tcells improvestheefficacyof adoptivetherapyof leukemia in mice. J Clin Invest 2010; 120: 3722-3734.
18. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor anti-gen-specific effector cells that traffic to the tumor. J Immunol 2005; 174: 7516-7523. (Pubitemid 40806254)
19. + Tcell- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 2004; 285: 25-40. (Pubitemid 38186583)